

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1-24. (Cancelled)

25. (Currently amended) An immunogenic polypeptide, ~~consisting essentially of~~ comprising a self IgE CH3 domain and one or more non-self IgE domains, wherein at least one of said non-self IgE domains ~~comprises~~ consists of an IgE sequence present in a non-placental mammal, and wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal, ~~and wherein said immunogenic polypeptide lacks a CH1 domain of IgE.~~

26. (Previously presented) The immunogenic polypeptide of claim 25, wherein said mammal is a human.

27. (Currently amended) The immunogenic polypeptide of claim 26, wherein the sequence of said immunogenic polypeptide is as set forth in ~~SEQ ID NO:4~~ SEQ ID NO:8.

28. (Previously presented) The immunogenic polypeptide of claim 25, wherein said non-placental mammal is selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.

29. (Previously presented) The immunogenic polypeptide of claim 25, wherein said polypeptide is capable of dimerizing to form a soluble immunogenic dimer effective to induce said anti-self IgE response in said mammal.

30. (Previously presented) The immunogenic polypeptide of claim 25, wherein one of said non-self IgE domains is an IgE CH2 domain, wherein one of said non-self IgE domains is an IgE CH4 domain, and wherein said self IgE CH3 domain is located between said IgE CH2 domain and said IgE CH4 domain.

31. (Previously presented) The immunogenic polypeptide of claim 25, wherein one of said non-self IgE domains is an IgE CH2 domain.

32. (Previously presented) The immunogenic polypeptide of claim 25, wherein one of said non-self IgE domains is an IgE CH4 domain.

33. (Currently amended) An immunogenic polypeptide, ~~consisting essentially of~~ comprising one or more non-self IgE domains; and at least an N-terminal half of a self IgE CH3 domain, wherein at least one of said non-self IgE domains ~~comprises~~ consists of an IgE sequence present in a non-placental mammal, and wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal.

34. (Previously presented) The immunogenic polypeptide of claim 33, wherein said mammal is a human.

35. (Currently amended) The immunogenic polypeptide of claim 34, wherein the sequence of said immunogenic polypeptide is as set forth in ~~SEQ ID NO:4~~ SEQ ID NO:8.

36. (Previously presented) The immunogenic polypeptide of claim 33, wherein said non-placental mammal is selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.

37. (Previously presented) The immunogenic polypeptide of claim 33, wherein said polypeptide is capable of dimerizing to form a soluble immunogenic dimer effective to induce said anti-self IgE response in said mammal.

38. (Previously presented) The immunogenic polypeptide of claim 33, wherein one of said non-self IgE domains is an IgE CH2 domain, wherein one of said non-self IgE domains is an IgE CH4 domain, and wherein said at least an N-terminal half of a self IgE CH3 domain is located between said IgE CH2 domain and said IgE CH4 domain.

39. (Previously presented) The immunogenic polypeptide of claim 33, wherein one of said non-self IgE domains is an IgE CH2 domain.

40. (Previously presented) The immunogenic polypeptide of claim 33, wherein one of said non-self IgE domains is an IgE CH4 domain.

41-54. (Cancelled)